Emzin 10Mg

COMPOSITION

Emzin 10 Tablet Each film coated tablet contains Empagliflozin INN 10 mg. Emzin 25 Tablet Each film coated tablet contains Empagliflozin INN 25 mg. 

DESCRIPTION

EMZIN tablets contain empagliflozin, an orally active inhibitor of the sodium glucose co-transporter 2 (SGLT2).

INDICATION

Emzin is indicated for the treatment of: Type 2 diabetes mellitus as monotherapy (if metformin inappropriate). Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemia control). 

CONTRAINDICATIONS

Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, diabetic ketoacidosis. 

CAUTIONS

Cardiovascular disease (increased risk of volume depletion), complicated urinary tract infections-consider temporarily interrupting treatment, concomitant antihypertensive therapy (increased risk of volume depletion), elderly patients aged over 75 years (increased risk of volume depletion), heart failure, history of hypotension (increased risk of volume depletion), patients at increased risk of volume depletion, predisposition to fluid disturbances e.g. gastro-intestinal illness, concomitant use of diuretics (increased risk of volume depletion). 

CAUTIONS, FURTHER INFORMATION

Volume depletion: Correct hypovolemia before starting treatment. Consider interrupting treatment if volume depletion occurs. 

SIDE EFFECTS

Common or very common: Genital infection, hypoglycemia (in combination with insulin or sulfonylurea), polyuria, pruritus, urinary tract infection. Uncommon: Dysuria, volume depletion. 

DRUG INTERACTIONS

Diuretics: Co-administration of Empagliflozin with diuretics resulted in increased urine volume. Insulin or Insulin Secretagogues: Co-administration of Empagliflozin with insulin or insulin Secretagogues increases the risk for hypoglycemia. 

The ACME Laboratories Ltd